Related Experiment Video
Updated: Feb 4, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism
James Peek1, Mirjana Lilic2, Daniel Montiel1
1Laboratory of Genetically Encoded Small Molecules, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.
Abstract:
Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (RifR). As resistance mechanisms found in clinical settings may also occur in natural environments, here we postulated that bacteria could have evolved to produce rifamycin congeners active against clinically relevant resistance phenotypes. We survey soil metagenomes and identify a tailoring enzyme-rich family of gene clusters encoding biosynthesis of rifamycin congeners (kanglemycins, Kangs) with potent in vivo and in vitro activity against the most common clinically relevant RifR mutations. Our structural and mechanistic analyses reveal the basis for Kang inhibition of RifR RNAP. Unlike Rifs, Kangs function through a mechanism that includes interfering with 5'-initiating substrate binding. Our results suggest that examining soil microbiomes for new analogues of clinically used antibiotics may uncover metabolites capable of circumventing clinically important resistance mechanisms.
Insights
New rifamycin-like compounds called kanglemycins combat antibiotic resistance. Discovered in soil, these kanglemycins (Kangs) effectively target resistant bacterial RNA polymerases, offering hope against drug-resistant infections.
Area of Science:
- Microbiology
- Molecular Biology
- Drug Discovery
Background:
- Rifamycin antibiotics (Rifs) are crucial for treating bacterial infections like tuberculosis by inhibiting bacterial RNA polymerases (RNAPs).
- Increasing antibiotic resistance (RifR) to Rifs threatens their clinical utility, necessitating the search for novel therapeutic agents.
- Resistance mechanisms observed clinically may also exist in natural environments, suggesting potential for discovering resistance-circumventing compounds.
Purpose of the Study:
- To investigate whether bacteria in natural environments produce rifamycin congeners active against clinically relevant rifamycin-resistant phenotypes.
- To identify and characterize novel rifamycin derivatives from soil metagenomes with potential to overcome existing resistance mechanisms.
Main Methods:
- Surveyed soil metagenomes to identify gene clusters involved in the biosynthesis of novel rifamycin congeners.
- Utilized structural and mechanistic analyses to elucidate the mode of action of identified compounds against resistant bacterial RNA polymerases.
- Performed in vitro and in vivo assays to evaluate the activity of kanglemycins against common clinically relevant RifR mutations.
Main Results:
- Identified a family of gene clusters encoding the biosynthesis of kanglemycins (Kangs), novel rifamycin congeners.
- Kangs demonstrated potent in vitro and in vivo activity against bacterial RNA polymerases harboring common clinically relevant RifR mutations.
- Mechanistic studies revealed that Kangs inhibit resistant RNAP by interfering with 5'-initiating substrate binding, a different mechanism than Rifs.
Conclusions:
- Soil microbiomes are a promising source for discovering novel antibiotic analogues capable of circumventing established resistance mechanisms.
- Kanglemycins represent a new class of compounds with potential therapeutic applications against rifamycin-resistant bacterial infections.
- Understanding the unique inhibitory mechanism of Kangs provides insights for designing next-generation antibiotics to combat resistance.
More Related Videos
Related Concept Videos
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
The Tree of Life - Bacteria, Archaea, Eukaryotes
Resistivity
Resistance
tRNA Activation
Equivalent Resistance

